43.93
0.65 (1.50%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Agios Pharmaceuticals, Inc. | Bullish | Bullish |
Stockmoo Score
|
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (RBC Capital, 25.20%) | Buy |
| Median | 50.50 (14.96%) | |
| Low | 46.00 (JP Morgan, 4.71%) | Hold |
| Average | 50.50 (14.96%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 45.37 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 02 Aug 2024 | 55.00 (25.20%) | Buy | 43.96 |
| JP Morgan | 13 Jun 2024 | 46.00 (4.71%) | Hold | 46.77 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Sep 2024 | Announcement | Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS) |
| 05 Sep 2024 | Announcement | Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024 |
| 06 Aug 2024 | Announcement | Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib |
| 01 Aug 2024 | Announcement | Agios Reports Business Highlights and Second Quarter 2024 Financial Results |
| 01 Aug 2024 | Announcement | Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused |
| 18 Jul 2024 | Announcement | Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024 |
| 15 Jun 2024 | Announcement | Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |